Beam Therapeutics (BEAM) Cash from Operations (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly Cash from Operations of 128513000.0 for Q1 2026, down 23.71% year-over-year from 168449239.69 in Q1 2025, and down 54.3% quarter-over-quarter from 83289000.0 in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) Cash from Operations (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Cash from Operations for 8 consecutive years, with 128513000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 23.71% year-over-year to 128513000.0; the TTM figure through Mar 2026 stood at 369731000.0 (down 5.22% YoY), while the FY2025 annual figure was 345102000.0, up 0.62% from the prior year.
- Cash from Operations fell to 128513000.0 in Q1 2026 per BEAM's latest filing, from 83289000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 218490000.0 in Q1 2022 and bottomed at 128513000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 55737000.0 across 5 years, with a median of 83009000.0 in 2024.
- On a YoY basis, Cash from Operations climbed as much as 666.36% in 2022 and fell as far as 3880.93% in 2022.
- Beam Therapeutics' Cash from Operations stood at 69191000.0 in 2022, then jumped by 295.22% to 135073000.0 in 2023, then slumped by 156.54% to 76365000.0 in 2024, then dropped by 9.07% to 83289000.0 in 2025, then tumbled by 54.3% to 128513000.0 in 2026.
- Business Quant data shows BEAM's Cash from Operations at 128513000.0 in Q1 2026, 83289000.0 in Q4 2025, and 81479000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | -66.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -66.10 Mn |
| Mar 31, 2026 | -128.51 Mn |
| Dec 31, 2025 | -83.29 Mn |
| Sep 30, 2025 | -81.48 Mn |
| Jun 30, 2025 | -76.45 Mn |
| Mar 31, 2025 | -103.88 Mn |
| Dec 31, 2024 | -76.37 Mn |
| Sep 30, 2024 | -88.13 Mn |
| Jun 30, 2024 | -83.01 Mn |
| Mar 31, 2024 | -99.75 Mn |
| Dec 31, 2023 | 135.07 Mn |
| Sep 30, 2023 | -89.78 Mn |
| Jun 30, 2023 | -84.67 Mn |
| Mar 31, 2023 | -109.82 Mn |
| Dec 31, 2022 | -69.19 Mn |
| Sep 30, 2022 | -74.50 Mn |
| Jun 30, 2022 | -52.28 Mn |
| Mar 31, 2022 | 218.49 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 3.01 Mn |